ArticleTranslational oncology2024

Targeting mutant p53 with arsenic trioxide: A preclinical study focusing on triple negative breast cancer.

Subhasree Rajaram et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.